Advanced Parkinson’s disease treatment patterns in Italy: an observational study interim analysis

References

• Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):1–11. doi: 10.1001/jama.2019.22360.
   Web of Science ®Google Scholar
• Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5–15. doi: 10.1111/j.1468-1331.2012.03866.x.
   PubMed Web of Science ®Google Scholar
• Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson’s disease. Semin Neurol. 2017;37(2):147–157. doi: 10.1055/s-0037-1602423.
   PubMed Web of Science ®Google Scholar
• Stocchi F. Prevention and treatment of motor fluctuations. Parkinsonism Relat Disord. 2003;9 Suppl 2(2):S73–S81. doi: 10.1016/s1353-8020(03)00021-x.
   PubMedGoogle Scholar
• Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol. 2018;16(8):1239–1252. doi: 10.2174/1570159x15666170510143821.
   PubMed Web of Science ®Google Scholar
• Aradi SD, Hauser RA. Medical management and prevention of motor complications in Parkinson’s disease. Neurotherapeutics. 2020;17(4):1339–1365. doi: 10.1007/s13311-020-00889-4.
   PubMed Web of Science ®Google Scholar
• Rastgardani T, Armstrong MJ, Gagliardi AR, et al. Understanding, impact, and communication of "OFF" periods in Parkinson’s disease: a scoping review. Mov Disord Clin Pract. 2018;5(5):461–470. doi: 10.1002/mdc3.12672.
   PubMedGoogle Scholar
• van der Velden RMJ, Broen MPG, Kuijf ML, et al. Frequency of mood and anxiety fluctuations in Parkinson’s disease patients with motor fluctuations: a systematic review. Mov Disord. 2018;33(10):1521–1527. doi: 10.1002/mds.27465.
   PubMed Web of Science ®Google Scholar
• Fackrell R, Carroll CB, Grosset DG, et al. Noninvasive ­options for ‘wearing-off’ in Parkinson’s disease: a clinical consensus from a panel of UK Parkinson’s disease specialists. Neurodegener Dis Manag. 2018;8(5):349–360. doi: 10.2217/nmt-2018-0020.
   PubMed Web of Science ®Google Scholar
• Jing XZ, Yang HJ, Taximaimaiti R, et al. Advances in the therapeutic use of non-ergot dopamine agonists in the treatment of motor and non-motor symptoms of Parkinson’s disease. Curr Neuropharmacol. 2023;21(5):1224–1240. doi: 10.2174/1570159X20666220915091022.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Antonini A, Costa J, et al. European academy of neurology/movement disorder Society-European section guideline on the treatment of Parkinson’s disease: i. Invasive therapies. Mov Disord. 2022;37(7):1360–1374. doi: 10.1002/mds.29066.
   PubMed Web of Science ®Google Scholar
• Dijk JM, Espay AJ, Katzenschlager R, et al. The choice between advanced therapies for Parkinson’s disease ­patients: why, what, and when? J Parkinsons Dis. 2020;10(S1):S65–S73. doi: 10.3233/jpd-202104.
   PubMedGoogle Scholar
• Isaacson SH, Pagan FL, Lew MF, et al. Should "on-demand" treatments for Parkinson’s disease OFF episodes be used earlier? Clin Park Relat Disord. 2022;7:100161. doi: 10.1016/j.prdoa.2022.100161.
   PubMedGoogle Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–442. doi: 10.1212/wnl.17.5.427.
   PubMed Web of Science ®Google Scholar
• Abbruzzese G, Antonini A, Barone P, et al. Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson’s disease. Neurol Sci. 2012;33(6):1319–1327. doi: 10.1007/s10072-012-0943-y.
   PubMed Web of Science ®Google Scholar
• Antonini A, Martinez-Martin P, Chaudhuri RK, et al. Wearing-off scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26(12):2169–2175. doi: 10.1002/mds.23875.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170. doi: 10.1002/mds.22340.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international ­pilot study. Mov Disord. 2007;22(13):1901–1911. doi: 10.1002/mds.21596.
   PubMed Web of Science ®Google Scholar
• Cova I, Di Battista ME, Vanacore N, et al. Validation of the Italian version of the non motor symptoms scale for Parkinson’s disease. Parkinsonism Relat Disord. 2017;34:38–42. doi: 10.1016/j.parkreldis.2016.10.020.
   PubMed Web of Science ®Google Scholar
• Galeoto G, Colalelli F, Massai P, et al. Quality of life in Parkinson’s disease: Italian validation of the Parkinson’s disease questionnaire (PDQ-39-IT). Neurol Sci. 2018;39(11):1903–1909. doi: 10.1007/s10072-018-3524-x.
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson’s disease questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26(5):353–357. doi: 10.1093/ageing/26.5.353.
   PubMed Web of Science ®Google Scholar
• Peto V, Jenkinson C, Fitzpatrick R, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4(3):241–248. doi: 10.1007/bf02260863.
   PubMed Web of Science ®Google Scholar
• Martínez-Martín P, Rodríguez-Blázquez C, Mario A, et al. Parkinson’s disease severity levels and MDS-Unified Parkinson’s disease rating scale. Parkinsonism Relat Disord 2015;21(1):50–54. doi: 10.1016/j.parkreldis.2014.10.026.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Rastgardani T, Gagliardi AR, et al. Barriers and facilitators of communication about off periods in Parkinson’s disease: qualitative analysis of patient, carepartner, and physician interviews. PLoS One. 2019;14(4):e0215384. doi: 10.1371/journal.pone.0215384.
   PubMed Web of Science ®Google Scholar
• Klingelhoefer L, Jitkritsadakul O, Bhidayasiri R. Objective measurement and monitoring of nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol. 2017;133:347–387. doi: 10.1016/bs.irn.2017.04.004.
   PubMed Web of Science ®Google Scholar
• Bjornestad A, Forsaa EB, Pedersen KF, et al. Risk and course of motor complications in a population-based incident Parkinson’s disease cohort. Parkinsonism Relat Disord. 2016;22:48–53. doi: 10.1016/j.parkreldis.2015.11.007.
   PubMed Web of Science ®Google Scholar
• Conti V, Izzo V, Russillo MC, et al. Gender differences in levodopa pharmacokinetics in levodopa-naïve patients with Parkinson’s disease. Front Med (Lausanne). 2022;9:909936. doi: 10.3389/fmed.2022.909936.
   PubMed Web of Science ®Google Scholar
• Picillo M, Nicoletti A, Fetoni V, et al. The relevance of gender in Parkinson’s disease: a review. J Neurol. 2017;264(8):1583–1607. doi: 10.1007/s00415-016-8384-9.
   PubMed Web of Science ®Google Scholar
• Brun L, Lefaucheur R, Fetter D, et al. Non-motor fluctuations in Parkinson’s disease: prevalence, characteristics and management in a large cohort of parkinsonian outpatients. Clin Neurol Neurosurg. 2014;127:93–96. doi: 10.1016/j.clineuro.2014.10.006.
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Abbruzzese G, Antonini A, et al. Reasons driving treatment modification in Parkinson’s disease: results from the cross-sectional phase of the REASON study. Parkinsonism Relat Disord. 2013;19(12):1130–1135. doi: 10.1016/j.parkreldis.2013.08.006.
   PubMed Web of Science ®Google Scholar
• Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology. 2002;59(3):408–413. doi: 10.1212/wnl.59.3.408.
   PubMed Web of Science ®Google Scholar
• Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13–20. doi: 10.1016/j.parkreldis.2017.09.018.
   PubMed Web of Science ®Google Scholar
• Stefani A, Tessitore A, Tambasco N, et al. Criteria for identification of advanced Parkinson’s disease: the results of the Italian subgroup of OBSERVE-PD observational study. BMC Neurol. 2022;22(1):41. doi: 10.1186/s12883-022-02554-z.
   PubMed Web of Science ®Google Scholar
• Zhang ZX, Chen H, Chen SD, et al. Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China. BMC Res Notes. 2014;7(1):65. doi: 10.1186/1756-0500-7-65.
   PubMedGoogle Scholar
• Garcia-Ruiz PJ, del Val J, Herranz A. Very long-standing Parkinson’s disease. Eur Neurol. 2013;70(3-4):172–174. doi: 10.1159/000351774.
   PubMed Web of Science ®Google Scholar
• Hely MA, Morris JG, Reid WG, et al. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190–199. doi: 10.1002/mds.20324.
   PubMed Web of Science ®Google Scholar
• Yust-Katz S, Sthneer S, Melamed E, et al. Long-term Parkinson’s disease–time for optimism. Biomed Pharmacother. 2008;62(4):233–235. doi: 10.1016/j.biopha.2007.12.014.
   PubMed Web of Science ®Google Scholar